Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Explore this paper's citation graph
Summary
Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.
- Type
- article
- Published
- 2013-06-19
- Cited by
- 2,177
- References
- 39
- Access
- Open access
- OpenAlex
- https://openalex.org/W2071549499
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205095265
Keywords
Ibrutinib, Bruton's tyrosine kinase, Chronic lymphocytic leukemia, Medicine, Cancer research
References
- A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells
- Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes.
- Involvement of RhoH GTPase in the Development of B-Cell Chronic Lymphocytic Leukemia
- Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
- Update on therapy of chronic lymphocytic leukemia.
- Defective B cell development and function in Btk-deficient mice.
- Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
- CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
- Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
- FCA: forget chemoimmunotherapy with alemtuzumab?
- Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
- ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia.
- Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice.
- Survival of leukemic B cells promoted by engagement of the antigen receptor.
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
- Bruton's Tyrosine Kinase Is Required for Activation of Iκb Kinase and Nuclear Factor κb in Response to B Cell Receptor Engagement
- Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma
- ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL).
Cited by
- Inhibidors de cinases com a estratègia terapèutica en neoplàsies limfoides
- Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center
- Reprint of: A review of cellular therapies for chronic lymphocytic leukemia.
- Emerging new anticancer biological therapies in 2013 (haematological malignancies)
- Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
- Bruton's tyrosine kinase inhibitors: lessons learned from bench-to-bedside (first) studies
- Ibrutinib and rituximab induced rapid response in refractory Richter syndrome
- CCL3 and CCL4 are biomarkers for BCR pathway activation and prognostic serum markers in diffuse large B cell lymphoma (DLBCL)
- Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
- Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
- Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
- Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support.
- Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells
- How to unleash mitochondrial apoptotic blockades to kill cancers?
- Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
- Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy
- Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro
- Transplantation in Chronic Lymphocytic Leukemia (CLL): does it still matter in the era of novel targeted therapies?
- Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis
Related papers
- Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
- The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View
- Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors
- Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
- Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
- Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors
- Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
- Bruton’s tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes